

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Anton MAYR et al.)	
)	Group Art Unit: Not Yet Assigned
Application No.: Not Yet Assigned)	
)	Examiner: Not Yet Assigned
Filed: July 21, 2006)	
)	
National Stage of International Application)	
No. PCT/EP2005/000582 under 35 U.S.C.)	
371, for MONOPARA IMMUNITY)	
INDUCERS BASED ON ATTENUATED)	
RABBIT MYXOMA VIRUSES)	

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08 and cited in the international search report. With exception of the U.S. patent, copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form. This Information Disclosure Statement is being filed with the above-referenced application.

The following is listed on the accompanying PTO/SB/08 and is in a non-English language:

1. European Patent Publication No. EP 0 669 133 A1 - U.S. 6,805,870 is a patent family member of this document.

In lieu of a statement of relevance or the translation of the non-English document, enclosed is an English-language international search report from the European Patent Office in the PCT international application, from which this national

phase U.S. application is derived, citing this document and setting forth the relevance thereof.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 21, 2006

By:

Ernest F. Chapman
Reg. No. 25,961

Enclosures
EFC/FPD/sci

AP20 Rec'd 21 JUL 2006

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	July 21, 2006 2006 2007082
				First Named Inventor	Anton MAYR et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	09914.0006

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-6,805,870 B1	10-19-2004	MAYR	

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 0 669 133 A1	08-30-1995	MAYR		NO

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		MOSSMAN, K. et al., "Myxoma Virus M-T7 a Secreted Homolog of the Interferon-γ Receptor, Is a Critical Virulence I-Actor for the Development of Myxomatosis in European Rabbits," Virology, Vol. 215, Article No. 0003, pp. 17-30, (1996).	
		UPTON, C. et al., "Myxoma Virus Expresses a Secreted Protein with Homology to the Tumor Necrosis Factor Receptor Gene Family that Contributes to Viral Virulence," Virology, Vol. 184, pp. 370-382, (1991).	
		SAITO, J. K. et al., "Attenuation of the Myxoma Virus and Use of The Living Attenuated Virus as an Immunizing Agent for Myxomatosis," The Journal of Infectious Diseases, Vol. 114, pp. 417-428, (December 1964).	
		MCCABE, V. J. et al., "Vaccination of Cats with an Attenuated Recombinant Myxoma Virus Expressing Feline Calicivirus Capsid Protein," Vaccine, Vol. 20, pp. 2454-2462, (2002).	
		NASH, P. et al., "Immunomodulation by Viruses: The Myxoma Virus Story," Immunological Reviews, Vol. 168, pp. 103-120, (1999).	
		MAYR, A. et al., "A New Concept in Prophylaxis and Therapy: Paramunization by Poxvirus Inducers," Pesq. Vet. Bras., Vol. 19, No. 3/4, pp.91-98, (July 1999).	
		BÜTTNER, M., "Principles of Paramunization: Option and Limits in Veterinary Medicine," Comp. Immun. Microbiol. Infect. Dis., Vol. 16, No. 1, pp. 1-10, (1993).	

Examiner Signature	Date Considered	
--------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.